Loading…
GE Healthcare and Global Medical Solutions Taiwan signed an exclusive license agreement to manufacture and commercialize Flutemetamol F-18 Injection (Vizamyl) in Taiwan. GMS Taiwan plans to file an NDA by end of 2021.
Global Medical Solutions Taiwan and Nihon Medi-Physics Co. Ltd. entered an exclusive agreement to develop and commercialize FACBC, a PET imaging agent for recurrent prostate cancer, in Taiwan. GMS Taiwan will submit the marketing authorization application and manufacture and distribute the product upon approval.